The OUtMATCH study: treating multiple allergies

It is recognised that of those children who do have allergies (about 8% of the population), 30–80% have responses to multiple foods. A double blind, placebo-controlled, randomised clinical trial, the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food Allergic Participants (OUtMATCH) study is a three phase study comparing omalizumab to placebo in children with multiple food allergies and is in its first phase. The study then goes on to phase two, a longer-term (52 weeks) treatment with omalizumab with oral immunotherapy and then the third stage will assess the introduction of allergenic foods into the diet at home after discontinuation of treatment with omalizumab or oral immunotherapy. Wood RA et al (N Engl J Med 2024;390:889–899) have reported the results of the first study. They have recuited subjects aged 1 to 55 years of age who were allergic to peanuts and at least two...
Source: Archives of Disease in Childhood - Category: Pediatrics Tags: Miscellanea Source Type: research